. .

 
Zuruecksetzen

Suchergebnis - Alexion Pharmaceuticals

Zeit Titel
14.06 12:35dpa-AFX: *ALEXION PHARMA SAYS POSITIVE PHASE 3 EXTENSION DATA FOR ULTOMIRIS PRESENTED AT EHA CONGRESS
25.05 05:18dpa-AFX: Biotech Stocks Facing FDA Decision In June 2019
25.05 05:18dpa-AFX: Biotech Stocks Facing FDA Decision In June 2019
25.05 05:17dpa-AFX: Biotech Stocks Facing FDA Decision In June 2019
25.05 05:17dpa-AFX: Biotech Stocks Facing FDA Decision In June 2019
25.04 12:53dpa-AFX: Alexion Pharmaceuticals Inc. Q1 adjusted earnings Beat Estimates
25.04 12:53dpa-AFX: Alexion Pharmaceuticals Inc. Q1 adjusted earnings Beat Estimates
25.04 12:42dpa-AFX: *ALEXION Q1 NON-GAAP EPS $2.39, 42% INCREASE FROM PRIOR YEAR
25.04 12:42dpa-AFX: *ALEXION Q1 TOTAL REVENUES $1.14 BLN, UP 23% FROM PRIOR YEAR
25.04 12:35dpa-AFX: *ALEXION Q1 GAAP EPS $2.61, UP 135% FROM LAST YEAR
20.03 12:07dpa-AFX: *ALEXION AND ZEALAND PHARMA ANNOUNCE COLLABORATION TO DEVELOP PEPTIDE THERAPIES FOR COMPLEMENT-MEDIATED DISEASES
20.03 11:37dpa-AFX: *ALEXION TO PROVIDE AFFIBODY WITH UPFRONT PAYMENT OF $25 MLN, WITH POTENTIAL FOR MILESTONES OF UP TO $625 MLN
20.03 11:36dpa-AFX: *ALEXION AND AFFIBODY AB ANNOUNCE PARTNERSHIP TO CO-DEVELOP ABY-039
04.02 13:01dpa-AFX: Alexion Pharmaceuticals Q4 18 Earnings Conference Call At 8:00 AM ET
04.02 12:34dpa-AFX: *ALEXION PHARMA Q4 NET LOSS $45 MLN OR $0.20/SHR VS. NET INCOME $30.0 MLN OR $0.13/SHR LAST YEAR
04.02 12:34dpa-AFX: *ALEXION PHARMA Q4 TOTAL REVENUES UP 24% TO $1.128 BLN
04.02 12:33dpa-AFX: *ALEXION PHARMA Q4 NON-GAAP EPS $2.14, CONSENSUS $1.82
31.01 12:33dpa-AFX: *ALEXION TO ACQUIRE CAELUM BASED ON PHASE 2 DATA
31.01 12:33dpa-AFX: *CAELUM TO RECEIVE UP TO $60 MLN FOR EQUITY INVESTMENT AND OPTION FEE
31.01 12:32dpa-AFX: *FORTRESS-FOUNDED CAELUM BIOSCIENCES TO RECEIVE $60 MLN IN STRATEGIC EQUITY INVESTMENT AND OPTION FEE

© 2000-2019 DZ BANK AG. Bitte beachten Sie die Nutzungsbedingungen |
2019 vwd Vereinigte Wirtschaftsdienste GmbH